Heretofore, a CD19(scFv)/CD3(scFv) bispecific T-cell engager (BiTE), blinatumomab, has been approved for clinical administration in refractory/relapsed B- acute lymphoblastic leukemia (B-ALL) and non-Hodgkin lymphoma (NHL) (43, 44). This evidence concerns the gene CD19 and non-Hodgkin lymphoma.